Results 81 to 90 of about 7,728 (235)

Nodular prurigo

Universidad Médica Pinareña, 2019
Paciente masculino de 63 años de edad, que acude a consulta por presentar hace varios meses lesiones elevadas muy pruriginosas, escoriadas y con costras hemáticas en miembros superiores, fundamentalmente en antebrazos en su superficie de extensión ...
Raúl Ernesto Pérez Morales, Yaima Gorrín Díaz   +1 more
doaj   +2 more sources

Racial and Gender Differences in the Presentation of Pruritus

Medicines, 2019
Background: Pruritus is a common disease symptom with a variety of etiologies known to reduce patient quality of life. We aimed to characterize the racial and gender differences in the presentation of pruritus for itch-related patient visits both within ...
Katherine A. Whang, Raveena Khanna, Jamael Thomas, Crystal Aguh, Shawn G. Kwatra   +4 more
doaj   +1 more source

Dupilumab in moderate‐to‐severe prurigo nodularis: Real‐world data from early access program

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Marie Jachiet, Clémentine Toussaint, Valérie Dorizy‐Vuong, Sophie Osdoit, Pierre‐André Becherel, Emmanuelle Amazan, Julia Vanlerberghe, Mahtab Samimi, Claudia Soares Barbosa, Carine Vera, Simmi Wiggins, Véronique Marcadé Fulcrand, Cédric Meyer, Laurent Misery, Jean‐David Bouaziz   +14 more
wiley   +1 more source

Clinical Characteristics and Risk Factors for Cutaneous Manifestations Associated With Nemolizumab in Atopic Dermatitis: A Multicenter Retrospective Study in Japan

The Journal of Dermatology, Volume 53, Issue 3, Page 399-409, March 2026.
ABSTRACT Nemolizumab, an anti‐interleukin‐31 receptor A monoclonal antibody, has been approved in Japan for treating atopic dermatitis (AD)‐associated pruritus. While it is effective for itch control, nemolizumab‐associated cutaneous adverse events have been increasingly recognized, yet their clinical features remain poorly characterized. In this study,
Wataru Sasaki, Ryo Saito, Kenta Suzuki, Daisuke Watanabe, Masako Minami‐Hori, Hirofumi Kamada, Hiroo Amano, Akihiko Uchiyama, Sei‐ichiro Motegi, Machiko Kamura, Kazunari Sugita, Noriko Kubota, Toshifumi Nomura, Maki Ozawa, Toshiya Takahashi, Takashi Yamakita, Kazumitsu Sugiura, Tetsuharu Ikegami, Ken Igawa, Yuka Kimura, Yoko Kataoka, Ryoichi Kamide, Masakazu Takahashi, Akio Tanaka, Mariko Sugawara‐Mikami   +24 more
wiley   +1 more source

The Itch-Scratch Cycle: A Review of the Mechanisms

Dermatology Practical & Conceptual, 2019
Background: Despite being one of the most common presenting dermatological symptoms, itching continues to perplex health care professionals because it is notoriously difficult to control.
Giulia Rinaldi
doaj   +1 more source

Prurigo Nodularis [PDF]

Proceedings of the Royal Society of Medicine, 1950
W P, ELFORD, F P, WEBER
openaire   +2 more sources

Enhanced PIEZO1 expression in mast cells of mastocytosis skin lesions: Relevance to Darier's sign

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Yoshiaki Kobayashi, Nobuhiro Nakano, Nguyen Quoc Vuong Tran, Yuki Nakamura, Lisa Minai, Takashi Okamoto, Daiki Nakagomi, Tatsuki R. Kataoka, Tatsuyoshi Kawamura, Atsuhito Nakao   +9 more
wiley   +1 more source

Wildfires and Atopic Diseases: A Review

Allergy, Volume 81, Issue 3, Page 651-662, March 2026.
ABSTRACT Wildfire smoke is a major environmental health threat that has increased in frequency and severity in recent years. A hazardous component of wildfire smoke is particulate matter ≤ 2.5 μm (PM2.5). There is evidence to suggest that exposure to wildfire PM2.5 may increase the risk of developing or exacerbating atopic diseases, such as asthma ...
Alex Ha, John R. Balmes, Maria L. Wei
wiley   +1 more source

Primary and Secondary Grzybowski’s Generalized Eruptive Keratoacanthoma: A New Perspective on Management, Clinical Features, and Prognosis

International Journal of Dermatology, Volume 65, Issue 3, Page 456-463, March 2026.
ABSTRACT Grzybowski's generalized eruptive keratoacanthoma (GEKA) is a rare variant of keratoacanthomas, characterized by hundreds to thousands of lesions, accompanied by pruritus, mucosal involvement, and comorbidities. Our aim was to analyze the clinical presentation, associated comorbidities, treatment strategies, and outcomes of GEKA.
Nicholas Florin Kormos, Carina Maria Petrenciu, Alin Stefan Vizitiu, Raluca Ghețe, Umer Nadir, Adrian Lucian Baican, Stanislav N. Tolkachjov   +6 more
wiley   +1 more source

Therapeutic advances in pruritus as a model of personalized medicine

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 3, Page 415-422, March 2026.
Recent advances in itch biology reveal that chronic pruritus arises from distinct neuroimmune pathways driven by cytokines, JAK, BTK and GPCRs. Targeted biologics and small molecule inhibitors such as dupilumab, nemolizumab, remibrutinib and JAK inhibitors precisely modulate these pathways, leading to a new era of personalized therapeutics in pruritus.
Kelsey Auyeung, Ramsey Kubofcik, Brian S. Kim   +2 more
wiley   +1 more source